| Literature DB >> 30858626 |
Beata Maciążek-Chyra1, Magdalena Szmyrka1,2, Marta Skoczyńska1,2, Renata Sokolik1,2, Joanna Lasocka2, Piotr Wiland1,2.
Abstract
OBJECTIVES: Relapsing polychondritis (RP) is a rare disease characterised by recurrent inflammation of the cartilaginous structures and proteoglycan-rich organs. The aim of this case series study is to share the 10-year clinical experience of our department in diagnosing RP patients in the context of data from available published studies.Entities:
Keywords: diagnostic criteria; relapsing polychondritis; symptoms
Year: 2019 PMID: 30858626 PMCID: PMC6409832 DOI: 10.5114/reum.2019.83234
Source DB: PubMed Journal: Reumatologia ISSN: 0034-6233
Three sets of diagnostic criteria for relapsing polychondritis
| McAdam et al. (1976) | Damiani et al. (1979) | Michet et al. (1986) | |
|---|---|---|---|
| Symptoms | Bilateral auricular chondritis | ||
| Required criteria | ≥ 3 | ≥ 3 (A) or ≥ 1 (A) and (B) or ≥ 2 (A) criteria and (C) | ≥ 2 (A) or ≥ 1 (A) and 2 (B) |
Case analysis of diagnostic criteria fulfilment
| Case | I | II | III | IV | V | VI | VII | VIII | IX | X |
|---|---|---|---|---|---|---|---|---|---|---|
| Fulfilment of criteria according to McAdam et al. | Yes | No | Yes | No | Yes | No | Yes | No | No | Yes |
| The number of present criteria according to McAdam et al. | 3 | 2 | 4 | 2 | 5 | 2 | 6 | 1 | 1 | 4 |
| Fulfilment of criteria according to Michet et al. | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | No | Yes |
| The number of present A criteria | 2 | 2 | 2 | 2 | 3 | 2 | 3 | 1 | 1 | 1 |
| The number of present B criteria | 0 | 0 | 2 | 0 | 1 | 0 | 4 | 0 | 0 | 2 |
| Fulfilment of criteria according to Damiani et al. | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | No | Yes |
| 3 McAdam’s criteria present | Yes | No | Yes | No | Yes | No | Yes | No | No | Yes |
| 1 McAdam’s criterion and positive histological biopsy | NA | Yes | Yes | NA | NA | Yes | NA | Yes | No | NA |
| 2 McAdam’s criteria and positive response to corticosteroids or dapsone | Yes | Yes | Yes | No | Yes | Yes | NA | No | NA | Yes |
NA – not applicable
Characteristic of first and diagnostically crucial symptoms along with age at the emergence of first and crucial manifestations and delay of diagnosis in the studied cases
| Case | I | II | III | IV | V | VI | VII | VIII | IX | X |
|---|---|---|---|---|---|---|---|---|---|---|
| Gender | Female | Female | Male | Female | Female | Female | Female | Male | Male | Male |
| The first symptom | Bronchial stenosis | Nasal chondritis | General symptoms | Laryngeal stenosis | Red ear | Red ear | Laryngeal stenosis | Red ear | Red ear | Arthritis |
| The diagnostically crucial symptom | Red ear | Red ear | Red ear | Laryngeal stenosis | Red ear | Red ear | Laryngeal stenosis | Red ear | Red ear | Red ear |
| Age at the emergence of the first symptom | 53 years | 52 years | 58 years | 69 years | 55 years | 55 years | 31 years | 37 years | 45 years | 68 years |
| Age at the diagnosis | 58 years | 53 years | 59 years | 73 years | 57 years | 58 years | 32 years | 37 years | 45 years (RP highly probable) | 73 years |
| Time from the first symptom to the diagnosis | 58 months | 9 months | 6 months | 41 months | 8 months | 21 months | 15 months | 4 months | 2 months | 48 months |
| Time from the crucial symptom to the diagnosis | 34 months | 2 months | 2 months | 41 months | 8 months | 21 months | 15 months | 4 months | Diagnosis not yet confirmed | 15 months |
Fig. 1Inflammation of pinna.
Fig. 2Episcleritis.
Relapsing polychondritis manifestations in individual cases
| Case | I | II | III | IV | V | VI | VII | VIII | IX | X | Total number of cases |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gender | Female | Female | Male | Female | Female | Female | Female | Male | Male | Male | 10 |
| Auricular chondritis | Yes (bilateral) | Yes (bilateral) | Yes (bilateral) | No | Yes (bilateral) | Yes (bilateral) | Yes (bilateral) | Yes (bilateral) | Yes (bilateral) | Yes (unilateral) | 9 |
| Nasal chondritis | Yes | Yes | Yes | Yes | Yes | Yes | Yes (nasal bridge collapse) | No | No | No | 7 |
| Respiratory tract chondritis | Yes (bronchial and subglottic stenosis) | No | No | Yes (laryngeal stenosis, tracheotomy, tracheomalacia) | Yes (laryngeal oedema) | No | Yes (laryngeal stenosis, tracheotomy, tracheal and bronchial stenosis) | No | No | Yes (thickening of the bronchial walls) | 5 |
| Arthritis | No | No | Yes (confirmed by USG) | No | Yes (confirmed by USG) | No | Yes (confirmed by USG) | No | No | Yes (confirmed by USG) | 4 |
| Ocular inflammation | No | No | Yes (episcleritis) | No | Yes (scleritis) | No | Yes (scleritis) | No | No | No | 3 |
| Audio-vestibular damage | No | No | No | No | No | No | Yes (hearing loss in the left ear – vestibular damage) | No | No | Yes (progressive hearing loss) | 2 |
| Haematological features | No | No | Yes (anaemia) | Yes (anaemia) | No | No | No | No | No | No | 2 |
| Cardiac involvement | Yes (valvular disease) | Yes (valvular disease) | Yes (arrhythmia) | No | No | No | No | No | No | Yes (valvular disease) | 4 |
| Vascular involvement | No | No | Yes (iliac arteries aneurysms) | Yes (dilatation of the ascending aorta) | No | No | No | No | No | No | 2 |
| Renal involvement | No | No | Yes (erythrocyturia) | No | No | No | No | No | No | No | 1 |
| Costal chondritis | No | No | No | No | No | No | Yes | No | No | No | 1 |
| Skin lesions | No | No | No | No | No | No | No | No | No | No | 0 |
| Nervous system involvement | No | No | No | No | No | No | No | No | No | No | 0 |
| General symptoms | No | No | Yes (fever, weight loss, fatigue) | No | No | No | No | No | No | No | 1 |
| Total number of manifestations | 4 | 3 | 9 | 3 | 3 | 2 | 8 | 1 | 1 | 5 | – |
Selected laboratory results in individual cases
| Case/Gender | ESR n: 0–10 (mm/h) | CRP n: 0–5 (mg/l) | Hb n: F: 12–16, M: 14–18 (g/dl) | ANA n: < 1 : 100 | ANCA n: negative |
|---|---|---|---|---|---|
| I/Female | 28 | 7.46 | 14.0 | Negative | Negative |
| II/Female | 14 | 1.39 | 13.4 | Negative | Negative |
| III/Male | 124 | 128.0 | 9.5 | Positive 1 : 320 (ENA negative) | Negative |
| IV/Female | 11 | 0.61 | 10.1 | Negative | Negative |
| V/Female | 9 | 0.34 | 13.6 | Positive 1 : 320 (ENA negative) | Negative |
| IV/Female | 15 | 0.45 | 14.6 | Positive 1 : 320 SSA+++ | Negative |
| VII/Female | ND | 0.39 | 12.8 | Negative | Negative |
| VIII/Male | 4 | 1,73 | 16.7 | Negative | Negative |
| IX/Male | 17 | 3.3 | 13.7 | Positive 1 : 320 (ENA negative) | Negative |
| X/Male | 7 | 1.58 | 13.9 | Negative | Negative |
ESR – erythrocyte sedimentation rate; CRP – C-reactive protein; Hb – haemoglobin; ANA – positive antinuclear antibodies; ENA – extractable nuclear antigens; ANCA – antineutrophil cytoplasmic antibody; ND – no data.